Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis

Author：            

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.4, 2015-01, pp. : 959-967

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 347-352

Science Publishers

Access to resources Recommend Favorite

Expression and clinical significance of vascular endothelial growth factor and fmsrelated tyrosine kinase 1 in colorectal cancer

By        

Oncology Letters, Vol. 9, Iss. 5, 2015-01 ,pp. : 2414-2418

Spandidos Publications

Access to resources Recommend Favorite

Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis

By Sher Amna   Wu Shenhong  

Acta Oncologica, Vol. 50, Iss. 7, 2011-10 ,pp. : 997-1005

Informa Healthcare

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 1, 2007-01 ,pp. : 59-71

Bentham Science Publishers

Access to resources Recommend Favorite